What's new in molecular genetic pathology 2021: Solid tumors and NGS panel selection

Guoli Chen, Patricia C. Tsang

Research output: Contribution to journalArticlepeer-review

Abstract

The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.

Original languageEnglish (US)
Pages (from-to)421-422
Number of pages2
JournalJournal of Pathology and Translational Medicine
Volume55
Issue number6
DOIs
StatePublished - Nov 2021

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Fingerprint

Dive into the research topics of 'What's new in molecular genetic pathology 2021: Solid tumors and NGS panel selection'. Together they form a unique fingerprint.

Cite this